Antares Pharma (NASDAQ: ATRS) reported Q1 EPS of ($0.05), in-line with the analyst estimate of ($0.05). Revenue for the quarter came in at $8.3 million versus the consensus estimate of $9.22 million.

For earnings history and earnings-related data on Antares Pharma (ATRS) click here.